Urinary Incontinence Clinical Trials

Find Urinary Incontinence Clinical Trials Near You

A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 22
Healthy Volunteers: f
View:

• Female at least 22 years old

• Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency

• Provocative pad weight of greater than 11.0 grams

• Candidate for surgical intervention

• Negative urinalysis

• Normal cystourethroscopy

• Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)

• Willing and able to sign informed consent and comply with trial follow-up requirements

Locations
United States
Colorado
University of Colorado
RECRUITING
Denver
Nebraska
CHI Health Research Center
RECRUITING
Omaha
Other Locations
France
Hôpital de la Conception - Marseille
RECRUITING
Marseille
CHU de Nantes
RECRUITING
Nantes
Pitié Salpêtrière University Hospital Paris
RECRUITING
Paris
Contact Information
Primary
Lisa Draper
USLDR@COLOPLAST.COM
612-834-7494
Backup
Matt Kelly, PhD
usmtk@coloplast.com
612-469-8882
Time Frame
Start Date: 2021-01-26
Estimated Completion Date: 2032-05-31
Participants
Target number of participants: 167
Treatments
Experimental: Adjustable Continence Therapy for Women
Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
Sponsors
Leads: Uromedica

This content was sourced from clinicaltrials.gov